NEW YORK (GenomeWeb News) – Clinical research organization Covance said after the close of the market on Wednesday that it will acquire Merck's Seattle-based gene expression laboratory.

Although the Princeton, NJ-based firm did not disclose the price of the acquisition, it said that Merck had committed to a five-year genomic analysis services contract worth $145 million as part of the deal. The lab performs genotyping, gene sequencing, and gene expression profiling services. The firms did not provide revenue figures for the lab.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.